Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a pioneer in metabolically healthy weight loss, today announced it has passed critica...

Allurion Technologies has achieved key FDA milestones and entered a transaction to exchange all outstanding debt, aiming to become debt-free. Additionally, the company announced a $5 million private placement financing.

Medtimo files patent infringement complaint against Allurion Technologies. The complaint seeks to protect Medtimo's balloon system technology and alleges that Allurion infringes three Medtimo patents. Medtimo Inc, a wholly owned subsidiary of Biorad Medisys Private Limited, has announced that it has filed a patent infringement complaint in the U.S. District Court of the District of Delaware against Allurion Technologies, Inc. Medtimo says its complaint details how Allurion's gastric balloon system infringes upon Medtimo's intellectual property. This definitive action follows Allurion's recent unsuccessful challenge of Medtimo's patent rights in the U.S. Patent and Trademark Office (USPTO). The complaint alleges that Allurion has infringed three key Medtimo patents, and is a refiling of a previous complaint filed in 2023, but with two additional patents that were awarded by the USPTO to Medtimo later in 2023 and 2024. The complaint specifically alleges infringement on three key patents, including U.S. Patent No. 10,463,520, U.S. Patent No. 11,779,482, and U.S. Patent No. 11,974,934, and Medtimo stands fully prepared to vigorously protect its valuable technology. "Medtimo has a long-standing commitment to developing and protecting our intellectual property, which is a cornerstone of our business," said Paul Hickey, CEO of Medtimo. "Allurion's products, including their gastric balloon system, allegedly utilise technology covered by our patents, and we are prepared to protect our innovations against infringers. This is a necessary step to protect our balloon system technology and the significant investments we've made in research and development, solidifying our position as a leader in the U.S. market." Allurion Technologies recently announced that Milena Alberti-Perez had resigned from its Board of Directors and as chairperson of the Audit Committee, effective September 30, 2025. According to the statement, Alberti-Perez's resignation was not due to "any disagreement with management, the board, or on any matter relating to the company's operations, policies, or practices."